Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis

光化性角化病患者的皮肤癌风险和风险预测

基本信息

项目摘要

PROJECT SUMMARY Research: Actinic keratoses (AKs) are pre-cancerous skin lesions that arise in the setting of chronic sun exposure and affect tens of millions of people in the United States each year. AKs have a risk of transformation to cutaneous squamous cell carcinoma. The majority of AK clinical care and research focuses on the individual AK and its risk of malignant transformation. However, there is evidence that the presence of AKs may be associated with increased risk of squamous cell carcinoma and other types of skin cancer (melanoma and basal cell carcinoma) for the patient as a whole. Though they are not typically used this way, AKs may be an important clinical biomarker of skin cancer risk, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Unfortunately, there are no specific recommendations for clinicians to follow for skin cancer surveillance or early detection in patients with AKs. This project will address key knowledge gaps: to examine the absolute risks of skin cancer in patients with AKs, which are unknown (Aim 1); to understand the care currently being provided to patients with AKs, which is uncharacterized (Aim 2); and to develop a skin cancer risk prediction model for patients with AKs, which has not previously been done (Aim 3). The overarching goal is to provide evidence to guide clinical care and form the foundation for future recommendations on skin cancer surveillance and early detection in patients with AKs, a large and high-risk group. Candidate: Dr. Mackenzie Wehner, MD MPhil is an Assistant Professor of Health Services Research and of Dermatology at MD Anderson Cancer Center. She completed her undergraduate degree at Yale University, medical school at Stanford University, a Master's in Epidemiology at the University of Cambridge, and residency and post- doctoral research fellowship at the University of Pennsylvania. Her career goal is to become an independent, R01-funded physician scientist in patient-oriented skin cancer research and through her research to decrease the burden of skin cancer in the United States. Environment: During this award period Dr. Wehner will devote at least 75% of her time to research and 20% to clinical care of patients at high risk of skin cancer, including those with AKs. Her primary mentor, Dr. Sharon Giordano, and co-mentor, Dr. David Margolis, are proven mentors and experts in patient-oriented research in cancer. The exceptional training environment in cancer research at MD Anderson will offer Dr. Wehner an outstanding opportunity to launch her career as an independent physician-scientist. Career Development: Dr. Wehner will have support from an experienced and diverse advisory committee and will focus her training on developing skills and experience in 1) health services research and large administrative datasets, 2) risk prediction modeling and tools development, and 3) incorporating genetic data in epidemiologic analyses. Completion of the proposed research and career development plan will serve as a platform upon which Dr. Wehner can successfully transition to independence and pursue an impactful career focused on patient-oriented skin cancer research.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mackenzie Rachel Wehner其他文献

Mackenzie Rachel Wehner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mackenzie Rachel Wehner', 18)}}的其他基金

Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis
光化性角化病患者的皮肤癌风险和风险预测
  • 批准号:
    10610895
  • 财政年份:
    2022
  • 资助金额:
    $ 26.04万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.04万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了